Login to Your Account



BioNumerik Starts Phase III with Improved Chemo Drug

By Trista Morrison


Friday, February 8, 2008
BioNumerik Pharmaceuticals Inc. started a pivotal Phase III trial comparing Karenitecin (BNP1350) with GlaxoSmithKline plc's Hycamtin (topotecan) in relapsed ovarian cancer. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription